Session » Rheumatoid Arthritis - Clinical Aspects Poster I
-
Abstract Number: 427
The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis
-
Abstract Number: 429
Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment
-
Abstract Number: 430
Adoption of Treat to Target Management in the Context of Achievable Goals and Satisfaction in RA
-
Abstract Number: 431
Treatment Target in a Disease Activity Score Steered Treatment Protocol in Early Arthritis Patients: Low Disease Activity or Remission
-
Abstract Number: 433
Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population
-
Abstract Number: 434
Duration of Remission By Currently Available Criteria Can Predict Physical Functioning, but Not Radiological Progression in Early Rheumatoid Arthritis Patients
-
Abstract Number: 436
Ultrasonographic Disease Activity in Rheumatoid Arthritis Patients Who Are in Clinical Remission According to Different Remission Criteria: Should We Insist on Achieving Boolean Remission?
-
Abstract Number: 437
Is Mode of Action Important When Switching Biologic Monotherapy in Rheumatoid Arthritis? Drug Adherence Results from the Swedish Ssatg Registry
-
Abstract Number: 440
Clinical Characteristics of Rheumatoid Arthritis Patients Achieving HAQ Remission with 6 Months of Biologic Treatment
-
Abstract Number: 441
Ultrasound Assessment of Early Response to Certolizumab Pegol Can Predict Future Response in Patients with Rheumatoid Arthritis
-
Abstract Number: 442
Use of Adjunctive Neuroregulatory Medication to Improve Etanercept Treatment Response for Patients with Inflammatory Arthritis: A Pilot Study
-
Abstract Number: 444
TNF Inhibitor Use Across Countries in Two Time Periods Using the Meteor Database
-
Abstract Number: 447
Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status
-
Abstract Number: 448
A Majority of Early Rheumatoid Arthritis (ERA) Patients Reach Remission By 6 Months in Usual Rheumatology Care
-
Abstract Number: 449
Change from SC to IV Abatacept and Back in Patients with Rheumatoid Arthritis As Simulation of a Vacation: A Prospective Phase IV, Open Label Trial (A-BREAK)
-
Abstract Number: 450
Use of Tofacitinib in a Real World Setting: Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial
-
Abstract Number: 451
Efficacy of Tofacitinib in a Real World Setting Using the Database Jointman
-
Abstract Number: 452
Associations Between Arthritis Patient, Disease-Specific and Provider Characteristics and Medication Information Source Use
-
Abstract Number: 453
Highly Elevated Rheumatoid Factor Is a Risk Factor for Abatacept Treatment Failure in Japanese Patients with Rheumatoid Arthritis
-
Abstract Number: 454
No Sex Bias in the Escalation of Therapy in the Treatment of Early Inflammatory Arthritis
-
Abstract Number: 455
Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care
-
Abstract Number: 457
RA Patients with Medicare Only Insurance Have Similar Clinical Outcomes As Patients with Private Insurance Despite Having Less Access to Biologics
-
Abstract Number: 458
First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network
-
Abstract Number: 460
Changes in Body Composition and Metabolic Profile during Treatment with Tocilizumab in Patients with Rheumatoid Arthritis
-
Abstract Number: 461
Etanercept Has a Better Retention Rate at 10 Years Than Adalimumab in Patients with Rheumatoid Arthritis. Results from Rhumadata®: A Real-Life Clinical Database and Registry
-
Abstract Number: 462
Radiographic Progression in Patients with Early Rheumatoid Arthritis Has Not Become Milder over the Past Decades
-
Abstract Number: 463
Treatment with Biologic Agents for RA in Patients with MTX-Associated Lymphoproliferative Disorders
-
Abstract Number: 464
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
-
Abstract Number: 466
Clinical Factors, Anti-Citrullinated Peptide Antibodies and MRI-Detected Subclinical Inflammation in Relation to Progression from Clinically Suspect Arthralgia to Arthritis
-
Abstract Number: 467
Clinical Outcomes of Patients with Active Rheumatoid Arthritis with Normal Acute-Phase Reactant Values
-
Abstract Number: 468
Clinical and Ultrasonographic Inflammation in DMARD-Naïve Early Rheumatoid Arthritis (RA) – Impact of the 2010 ACR/EULAR Classification Criteria Versus the 1987 ACR Classification Criteria
-
Abstract Number: 469
Window of Opportunity to Achieve Major Outcomes in Early Rheumatoid Arthritis Patients: How Persistence with Therapy Matters
-
Abstract Number: 470
Disease Outcome in Patients Fulfilling the 2010 Classification Criteria for Rheumatoid Arthritis: The Impact of the Different Criteria Components
-
Abstract Number: 471
Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titer on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab
-
Abstract Number: 472
Quality Assessment in Clinical Management of Patients with Rheumatoid Arthritis. Are We Using the “Treat to Target” Strategy?
-
Abstract Number: 473
Methotrexate, Blood Pressure and Arterial Wave Reflection in Rheumatoid Arthritis
-
Abstract Number: 474
Trends in the Use of Opiates in Rheumatoid Arthritis (RA) Compared to Non-RA: A Population Based Study in 2003-2012
-
Abstract Number: 475
Benefits of Achieving Comprehensive Disease Control (CDC) in Patients with Rheumatoid Arthritis: Evidence from the Corrona Registry
-
Abstract Number: 476
Clinical Disease Activity Measures Change Substantially and Irregularly over Time in Individual Rheumatoid Arthritis Patients Considered to be in Steady State
-
Abstract Number: 477
On-Demand Use of Etanercept Only for Disease Flares Reduced the Disease Activity Score and Structural Damage Equivalent to Fully-Use of Etanercept in RA Patients
-
Abstract Number: 478
Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients
-
Abstract Number: 479
How to Recruit Anti-CCP Positive Patients from Primary Care
-
Abstract Number: 480
Comparative 10-Year Retention Rates of Adalimumab Used in Mono and Combination Therapy in Rheumatoid Arthritis (RA) Patients from the Rhumadata Clinical Database and Registry
-
Abstract Number: 481
Time to Disease-Modifying Anti-Rheumatic Drug Treatment for New Patients with Rheumatoid Arthritis – Single Center Experience
-
Abstract Number: 482
Erosions in the Foot at Baseline Are Predictive of Orthopedic Shoe Use after 10 Years of Treat to Target Therapy
-
Abstract Number: 483
Antibody to Malondialdehyde-Acetaldehyde (MAA) Adducts Serve As Biomarkers of Treatment Response in Rheumatoid Arthritis
-
Abstract Number: 484
Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use
-
Abstract Number: 485
Evaluate the Dose Efficacy Response Relationship of Baricitinib in Patients with Rheumatoid Arthritis
-
Abstract Number: 486
Persistence Among Rheumatoid Arthritis Patients Initiating Intravenous or Subcutaneous Anti-Tumor Necrosis Factor Therapy in a Large US Registry Cohort
-
Abstract Number: 487
Early Rheumatoid Arthritis Patients in the Worse Disease Trajectory Group Fail to Achieve Improvement in Physical Function
-
Abstract Number: 488
Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry
-
Abstract Number: 489
Drug Survival and Toxicity of Methotrexate Monotherapy in Daily Clinical Practice. Results from an Early Arthritis Clinic
-
Abstract Number: 490
Personalizing the Treat to Target Approach in Rheumatoid Arthritis
-
Abstract Number: 491
A Paradigm Shift in the Disease Assessment of Rheumatoid Arthritis : From Blood to Urine Testing
-
Abstract Number: 492
Correlations Between Clinical, Laboratory and Ultrasound Joint Examination in RA Patients Treated with Rituximab
-
Abstract Number: 493
Diagnostic Delay in Early Arthritis: Ten Years-Experience of a Single Center
-
Abstract Number: 494
High C-Reactive Protein at Baseline Is Associated with Long-Term Treatment Persistence in Patients with Rheumatoid Arthritis Treated with Rituximab
-
Abstract Number: 496
Increased Serum Lipids Under Tocilizumab Is Not Influenced By Methotrexate
-
Abstract Number: 497
Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry
-
Abstract Number: 498
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
-
Abstract Number: 499
Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity
-
Abstract Number: 500
Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis
-
Abstract Number: 501
Change in RF Titers Reflects RA Disease Activity and Predicts Therapeutic Response during TNF Inhibitor Therapy; Patients with a Continuous Reduction of Serum RF Levels Show Good Response
-
Abstract Number: 502
Decreased Vaccine Responses in Rheumatoid Arthritis Patients Receiving Anti-TNF Treatment and Relationship to B Cell Subsets
-
Abstract Number: 503
Predictors for Attaining Remission at Two Consecutive Visits in Newly Diagnosed Early RA Patients
-
Abstract Number: 504
Influence of CDAI Measurement on the Decision of Community Rheumatologists to Initiate or Change Biologic Treatment
-
Abstract Number: 505
Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry
-
Abstract Number: 506
Evaluation of Persistence and Outcomes in Patients Treated with TNF and Non-TNF Biologics Following Treatment Clinical Pathway in Rheumatoid Arthritis
-
Abstract Number: 507
Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis
-
Abstract Number: 508
Impact of Race on Patient Global Scores and the Misclassification of Disease Activity
-
Abstract Number: 509
In Early Undifferentiated Polyarthritis, 14-3-3η Seroreversion or Sustained Negativity Is Associated with Better Radiographic Outcomes, Even in DAS-28 Remitters
-
Abstract Number: 510
Histologic Scoring of Arthroplasty Synovial Samples May Predict RA Flare
-
Abstract Number: 511
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
-
Abstract Number: 512
Physical Function and Inflammatory Activity in Rheumatoid Arthritis Patients. Is Disease Duration Important?
-
Abstract Number: 513
Cumulative Association of Genetic Variants with Rheumatoid Joint Damage Progression in Mexican Americans and European Americans
-
Abstract Number: 515
Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?